UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of September 2024
Commission File Number: 001-41084
NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-7996183
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On September 24, 2024, NeuroSense Therapeutics
Ltd. (the “Company”) issued a press release entitled “NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule.”
A copy of the press release is furnished herewith as Exhibit 99.1.
Also on September 24, 2024, the Company issued
a press release entitled “NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation,
its Lead Asset for ALS and Alzheimer’s” A copy
of the press release is furnished herewith as Exhibit 99.2.
This Report on Form 6-K, the press release attached
as Exhibit 99.1, and the first paragraph of the press release attached as Exhibit 99.2 are hereby incorporated by reference into the registrant’s
Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File No. 333-269306 and 333-260338), to be a part thereof from
the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
NeuroSense Therapeutics Ltd. |
|
|
|
Date: September 24, 2024 |
By: |
/s/ Alon Ben-Noon |
|
|
Alon Ben-Noon |
|
|
Chief Executive Officer |
3
Exhibit 99.1
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
CAMBRIDGE, Mass., September 24, 2024 /PRNewswire/ -- NeuroSense
Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases,
today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained
compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing.
To regain compliance with the Rule, the Company’s ordinary shares
were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved
on September 20, 2024. Therefore, the Nasdaq Listing Qualifications Staff considers the prior bid price deficiency matter now closed.
NeuroSense’s CEO, Alon Ben-Noon said, ” We are pleased to
have regained compliance with Nasdaq’s minimum bid price requirement, an important step that reflects our commitment to advancing PrimeC.
With the positive momentum following our Phase 2b trial results, we are looking forward to initiating the Phase 3 trial in the US and
continuing our discussions with potential partners.”
About NeuroSense
NeuroSense
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from
debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with
limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on
strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple
pathways associated with these diseases.
For additional
information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may
be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains “forward-looking statements”
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,”
“intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “target,” “aim,” “should,” “will” “would,” or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to
predict and include statements regarding initiating the Phase 3 trial for PrimeC in the US. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual
results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include
unexpected R&D costs or operating expenses, a delay in the reporting of additional results from PARADIGM clinical trial or a delay
in initiating the Phase 3 trial for PrimeC in the US, the timing of expected regulatory and business milestones, risks associated with
meeting with the FDA to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such
meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding
outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of
any product candidates of NeuroSense; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange
Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and
uncertainties affecting the Company is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with
the Securities and Exchange Commission on March 22, 2023. Forward-looking statements contained in this announcement are made as of this
date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Exhibit 99.2
NeuroSense Therapeutics Granted Key U.S. Patent
for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer’s
The Company’s intellectual property now covers the combination,
formulation, and method of use of PrimeC
Patent protection extends through 2042, adding four additional years
to PrimeC's IP umbrella
CAMBRIDGE, Mass., September
24, 2024, -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a late-clinical
stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the issuance of a pivotal
patent by the United States Patent and Trademark Office (USPTO). The newly granted patent, entitled “Compositions comprising Ciprofloxacin
and Celecoxib” (US Patent No. US 12,097,185), relates to the novel formulation of PrimeC, NeuroSense’s leading drug candidate
for the treatment of Amyotrophic Lateral Sclerosis (ALS). This patent is expected to extend PrimeC’s patent protection by an additional
four years, until 2042.
PrimeC is composed of ciprofloxacin
and celecoxib, two FDA-approved compounds in unique doses, formulated in a technology of slow release to synchronize their pharmacokinetic
(PK) profiles and enhance their therapeutic synergy. This innovative approach is designed to optimize the treatment efficacy in slowing
ALS progression.
The patent grant follows NeuroSense’s
recent clinical findings, where PrimeC demonstrated a 36% reduction in disease progression (p=0.009) and a 43% improvement in
survival rates compared to placebo, underscoring its potential as a breakthrough therapy for ALS.
Alon Ben-Noon, NeuroSense CEO
commented: “PrimeC is more than a combination of two FDA-approved compounds - it’s an innovative formulation that synchronizes
their pharmacokinetics to unleash their full therapeutic potential. The synergy between ciprofloxacin and celecoxib is designed to maximize
efficacy, pushing the boundaries of what’s possible in ALS treatment.”
About
ALS
Amyotrophic
lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years
from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1
billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
About
ALSFRS-R
Disease progression is measured by the ALS Functional
Rating Scale-Revised (ALSFRS-R), which is the most widely used ALS tracking tool accepted by the FDA, utilized by neurologists treating
ALS patients, in clinical trials, and by other regulators to determine disease progression. It tracks 12 changes in a person’s physical
abilities over time including functions such as: speech, walking, climbing stairs, dressing/hygiene, handwriting, turning in bed, cutting
food, salivation, swallowing, and breathing. A single point change on the ALSFRS-R has a significant impact on ALS patients, such as the
transition from independent feeding to requiring assistance or independent breathing to needing to use a machine ventilator.
About
PARADIGM
PARADIGM
is a prospective, multinational, randomized, double-blind, placebo-controlled Phase 2b (NCT05357950) clinical trial of PrimeC in ALS.
The trial included 68 participants living with ALS in Canada, Italy, and Israel. 96% of the trial participants who completed the 6-month
double-blind portion of the trial chose to receive treatment with PrimeC through a 12-month open label extension. Furthermore, to date
(June 2024) all participants that completed the 18-month trial treatment duration, requested to continue PrimeC, which is provided to
them in an Investigator Initiated Trial, not limited with time.
As previously
reported, in the 6-month double-blind segment of the trial, the data showed clinically meaningful signs of efficacy with a 29% difference
in favor of PrimeC vs placebo in analysis of the intent to treat (ITT) population. In the PP top-line analysis from PARADIGM, a
statistically significant slowing of disease progression was observed with a 37.4% (p=0.03) difference in ALSFRS-R in favor of PrimeC
vs placebo. Most patients enrolled in both the active and placebo arms of the trial were concurrently
treated with Riluzole, the ALS standard of care medication, indicating PrimeC slowed disease progression well beyond the level afforded
by the FDA approved ALS drug.
About
PrimeC
PrimeC,
NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved
drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor
neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit
the progression of ALS. NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing
functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC’s
biological activity. PrimeC was granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency.
About
NeuroSense
NeuroSense
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from
debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with
limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on
strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple
pathways associated with these diseases.
For additional
information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may
be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking
Statements
This press
release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other
than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained
in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,”
“could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,”
“plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject
to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding PrimeC as a potential
treatment for people with ALS. Further, certain forward-looking statements are based on assumptions as to future events that may not prove
to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated
or implied in the forward looking statements. These risks include unexpected R&D costs or operating expenses, a delay in the reporting
of additional results from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting
with the FDA to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting;
the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes
and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product
candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s
filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future.
More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the
Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2024 and NeuroSense’s subsequent filings
with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to
update such information except as required under applicable law.
For further
information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183
3
NeuroSense Therapeutics (NASDAQ:NRSNW)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
NeuroSense Therapeutics (NASDAQ:NRSNW)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024